Center for Targeted Therapeutics

描述（由申请人提供）：拟议的靶向治疗中心（CTT）是南卡罗来纳州（USC）的生物医学研究卓越中心（COBRE），其主要目标是吸引和促进有才华的年轻科学家的专业发展，他们有动力在治疗严重疾病方面发挥作用。CTT将设在南卡罗来纳州（USC）和南卡罗来纳州医科大学（MUSC）的SC药学院（SCCP），其中一名目标教师在南卡罗来纳州医学院（SOM）。该中心的业务包括四个研究项目，由四名目标初级教员（两名在USC-SCCP，一名在MUSC-SCCP，一名在USC-SOM）领导，具有功能基因组学，药物发现，神经科学和纳米颗粒药物输送方面的专业知识。该计划还将包括三个资源核心：功能基因组学核心（USC-SCCP），合成化学和药物发现核心（MUSC-SCCP）和显微镜和流式细胞术核心（USCSCCP），每个核心由一名主任和一名联合主任管理，他们将在项目开发中提供科学和知识建议，沿着技术支持。每个项目都将使用每个核心，除了一个项目，在MUSC，将不使用显微镜和流式细胞仪在南加州大学的核心。CTT将利用USC和MUSC在南卡罗来纳州药学院之间的现有整合，该学院处于两所大学之间共享的独特地位，两个校区都有强大的组件，以及一个开发良好的视频通信系统，可以实现无缝通信和教学和研究计划的共享。CTT将充分利用这两个机构的资源，药物发现和转化研究是优先考虑的重点，并且还与已经到位的IDEA计划相结合。CTT保护伞将涵盖几个对靶向治疗至关重要的科学领域，并涵盖多种疾病，其中包括与南卡罗来纳州人口特别相关的癌症和神经系统疾病。

DESCRIPTION (provided by applicant): The principal goal of the proposed Center for Targeted Therapeutics (CTT), a Center of Biomedical Research Excellence (COBRE) at the University of South Carolina (USC), is to attract and foster the professional development of talented junior scientists, who are motivated to make a difference in the treatment of serious diseases. The CTT will be located at the SC College of Pharmacy (SCCP) at the University of South Carolina (USC) and the Medical University of South Carolina (MUSC), with one of the target faculty at the USC School of Medicine (SOM). The Center operations include four research projects led by four target junior faculty members (two at USC-SCCP, one at MUSC-SCCP and one at USC-SOM), with expertise in functional genomics, drug discovery, neuroscience and nanoparticle drug delivery. The Program will also include three resource cores: the Functional Genomics Core (USC-SCCP), the Synthetic Chemistry and Drug Discovery Core (MUSC-SCCP) and the Microscopy and Flow Cytometry Core (USCSCCP), each managed by a Director and a co-Director, who will provide scientific and intellectual advice in project development, along with technological support. Each of the projects will be working with each of the cores, except that one project, based at MUSC, will not utilize the Microscopy and Flow Cytometry core at USC. The CTT will take advantage of the existing integration between USC and MUSC in the South Carolina College of Pharmacy, which is in the unique position of being shared between the two Universities, with strong components on both campuses, and a well-developed system of video communication that allows for seamless communication and sharing of teaching and research programs. The CTT will be well-positioned to take full advantage of the resources of both institutions, where drug discovery and translational research are strong priorities, and also interface with IDeA programs already in place. The CTT umbrella will encompass several scientific areas critical for targeted therapeutics and spanning multiple diseases among which are cancer and neurologic disorders that are particularly relevant to the South Carolina population.